Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy

Shares of Blueprint Medicines (BPMC) rallied 18.2% on Monday driven by investor enthusiasm following the company’s announcement of its 2025 corporate outlook and growth strategy, highlighting plans to build on its established R&D and commercial expertise.Blueprint’s commercial portfolio only comprises its lead drug Ayvakit (avapritinib), an inhibitor of KIT and PDGFRA proteins, which was initially approved in the United States and the EU to treat gastrointestinal stromal tumors in 2020. Later, the drug’s la ...